Synonym
SR-1555; SR 1555; SR1555
IUPAC/Chemical Name
1-(4-((4'-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-[1,1'-biphenyl]-4-yl)methyl)piperazin-1-yl)ethan-1-one
InChi Key
LTFVNEZXOPUABB-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H22F6N2O2/c1-15(31)30-12-10-29(11-13-30)14-16-2-4-17(5-3-16)18-6-8-19(9-7-18)20(32,21(23,24)25)22(26,27)28/h2-9,32H,10-14H2,1H3
SMILES Code
OC(C(F)(F)F)(C(F)(F)F)C(C=C1)=CC=C1C2=CC=C(CN3CCN(C(C)=O)CC3)C=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
SR1555 is a RORγ inverse agonist with an IC50 value of 1 μM. SR1555 also increases the frequency of T regulatory cells, as well as inhibits the expression of IL-17.
In vitro activity:
Synthetic RORγ ligands, such as SR1555, could potentially be developed to target both suppression of T(H)17 and stimulation of T regulatory cells, offering key advantages in targeting autoimmune diseases. This study identified SR1555 as able to inhibit T(H)17 cell development and function and increases the frequency of T regulatory cells.
Reference: ACS Chem Biol. 2012 Sep 21;7(9):1515-9. https://pubmed.ncbi.nlm.nih.gov/22769242/
In vivo activity:
SR1555 may have potential in obesity treatment. Chronic administration of SR1555 to obese diabetic mice resulted in a modest reduction in food intake. There was also a significant reduction in fat mass, resulting in reduced body weight and improved insulin sensitivity. Ex vivo analysis demonstrated that SR1555 induced expression of the thermogenic gene program in fat depots.
Reference: Mol Pharmacol. 2015 Jul;88(1):48-56. https://pubmed.ncbi.nlm.nih.gov/25904554/
Preparing Stock Solutions
The following data is based on the
product
molecular weight
460.42
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Solt LA, Kumar N, He Y, Kamenecka TM, Griffin PR, Burris TP. Identification of a selective RORγ ligand that suppresses T(H)17 cells and stimulates T regulatory cells. ACS Chem Biol. 2012 Sep 21;7(9):1515-9. doi: 10.1021/cb3002649. Epub 2012 Jul 9. PMID: 22769242; PMCID: PMC3448878.
2. Chang MR, He Y, Khan TM, Kuruvilla DS, Garcia-Ordonez R, Corzo CA, Unger TJ, White DW, Khan S, Lin L, Cameron MD, Kamenecka TM, Griffin PR. Antiobesity Effect of a Small Molecule Repressor of RORγ. Mol Pharmacol. 2015 Jul;88(1):48-56. doi: 10.1124/mol.114.097485. Epub 2015 Apr 22. PMID: 25904554; PMCID: PMC4468634.
In vitro protocol:
1. Solt LA, Kumar N, He Y, Kamenecka TM, Griffin PR, Burris TP. Identification of a selective RORγ ligand that suppresses T(H)17 cells and stimulates T regulatory cells. ACS Chem Biol. 2012 Sep 21;7(9):1515-9. doi: 10.1021/cb3002649. Epub 2012 Jul 9. PMID: 22769242; PMCID: PMC3448878.
In vivo protocol:
1. Chang MR, He Y, Khan TM, Kuruvilla DS, Garcia-Ordonez R, Corzo CA, Unger TJ, White DW, Khan S, Lin L, Cameron MD, Kamenecka TM, Griffin PR. Antiobesity Effect of a Small Molecule Repressor of RORγ. Mol Pharmacol. 2015 Jul;88(1):48-56. doi: 10.1124/mol.114.097485. Epub 2015 Apr 22. PMID: 25904554; PMCID: PMC4468634.
1: Chang MR, He Y, Khan TM, Kuruvilla DS, Garcia-Ordonez R, Corzo CA, Unger TJ, White DW, Khan S, Lin L, Cameron MD, Kamenecka TM, Griffin PR. Antiobesity Effect of a Small Molecule Repressor of RORγ. Mol Pharmacol. 2015 Jul;88(1):48-56. doi: 10.1124/mol.114.097485. Epub 2015 Apr 22. PubMed PMID: 25904554; PubMed Central PMCID: PMC4468634.
2: Haddadi MH, Negahdari B, Hajizadeh-Saffar E, Khosravi-Maharlooei M, Basiri M, Dabiri H, Baharvand H. Directed differentiation of regulatory T cells from naive T cells and prevention of their inflammation-mediated instability using small molecules. Clin Exp Immunol. 2020 Aug;201(2):205-221. doi: 10.1111/cei.13453. Epub 2020 Jun 8. PMID: 32403163; PMCID: PMC7366754.
3: Solt LA, Kumar N, He Y, Kamenecka TM, Griffin PR, Burris TP. Identification of a selective RORγ ligand that suppresses T(H)17 cells and stimulates T regulatory cells. ACS Chem Biol. 2012 Sep 21;7(9):1515-9. doi: 10.1021/cb3002649. Epub 2012 Jul 9. PMID: 22769242; PMCID: PMC3448878.
